Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus fingolimod in pediatric relapsing-remitting multiple sclerosis
2023-506516-40-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Ocrevus arm with Gilenya arm (2 arms). Primary endpoint: Protocol-defined annualized relapse rate (ARR). Planned start Feb 2022; status: authorised.
02
Drugs
ocrelizumabfingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2023-506516-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506516-40-00.